BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Yekkirala, A. S., Roberson, D. P., Bean, B. P., & Woolf, C. J. (2017). Breaking barriers to novel analgesic drug development. Nature reviews. Drug discovery, 16(8), 545–564. Added by: Dr. Enrique Feoli (15/06/2020, 14:45) |
 |
| Resource type: Journal Article DOI: 10.1038/nrd.2017.87 ID no. (ISBN etc.): 1474-1784 BibTeX citation key: Yekkirala2017 View all bibliographic details  |
Categories: Mendeley, Mendeley Subcategories: Analgesia Creators: Bean, Roberson, Woolf, Yekkirala Collection: Nature reviews. Drug discovery |
Views: 5/355
|
| Abstract |
|
Acute and chronic pain complaints, although common, are generally poorly served by existing therapies. This unmet clinical need reflects a failure to develop novel classes of analgesics with superior efficacy, diminished adverse effects and a lower abuse liability than those currently available. Reasons for this include the heterogeneity of clinical pain conditions, the complexity and diversity of underlying pathophysiological mechanisms, and the unreliability of some preclinical pain models. However, recent advances in our understanding of the neurobiology of pain are beginning to offer opportunities for developing novel therapeutic strategies and revisiting existing targets, including modulating ion channels, enzymes and G-protein-coupled receptors.
Added by: Dr. Enrique Feoli |